Abbott Laboratories (ABT)
market vs.
industry GROWTH & VALUE
| 12m Forecast Rolling | ||||
| PE Ratio (f) | 34.4 |
|
|
|
| PEG Ratio (f) |
|
|
||
| EPS Growth (f) | % |
|
|
|
| Dividend Yield (f) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 5.03 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 31st Dec | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | TTM | 2013E | 2014E | CAGR / Avg | |
| Revenue | $m | ||||||||||
| Operating Profit | $m | ||||||||||
| Net Profit | $m | ||||||||||
| EPS Reported | $ | ||||||||||
| EPS Normalised | $ | ||||||||||
| EPS Growth | % | ||||||||||
| PE Ratio | x | ||||||||||
| PEG | x | ||||||||||
| Profitability | |||||||||||
| Operating Margin | % | ||||||||||
| ROA | % | ||||||||||
| ROCE | % | ||||||||||
| ROE | % | ||||||||||
| Cashflow | |||||||||||
| Op. Cashflow ps | $ | ||||||||||
| Capex ps | $ | ||||||||||
| Free Cashflow ps | $ | ||||||||||
| Last ex-div: 11th Jul, paid: 15th Aug more... Dividends | |||||||||||
| Dividend ps | $ | ||||||||||
| Dividend Growth | % | ||||||||||
| Dividend Yield | % | ||||||||||
| Dividend Cover | x | ||||||||||
| Balance Sheet | |||||||||||
| Cash etc | $m | ||||||||||
| Working Capital | $m | ||||||||||
| Net Fixed Assets | $m | ||||||||||
| Net Debt | $m | ||||||||||
| Book Value | $m | ||||||||||
| Average Shares | m | ||||||||||
| Book Value ps | $ | +8.1% | |||||||||
FINANCIAL BRIEF: For the three months ended 31 March 2013, Abbott Laboratories revenues increased 2% to $5.38B. Net income before extraordinary items increased 55% to $544.7M. Revenues reflect Nutritionals Products segment increase of 9% to $1.7B, Diagnostics Products segment increase of 4% to $1.09B, All Other Countries segment increase of 4% to $3.84B. Net income benefited from Selling, general and administrative decrease of 3% to $1.79B (expense). more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 31st Mar '13) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: | 1 | 0 | 14 | 5 | 5 |
Abbott Laboratories (Abbott), is engaged in the discovery, development, manufacture, and sale of a portfolio of science-based health care products. Abbott operates in four business segments: diagnostics, medical devices, nutritionals and generic pharmaceuticals. Geographically, 30% of its revenue is generated in the United States; 30% in Western Europe, Canada, Japan and Australia, and 40% in the economies, including India, China, Russia and Brazil. In January 2013, the Company completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new independent biopharmaceutical company.
Directors: Miles White (Chmn.) 58, Thomas Freyman (CFO) 58, Hubert Allen (Exec. VP) 47, Richard Ashley (Exec. VP) 69, Brian Blaser (Exec. VP) 48, John Capek (Exec. VP) 51, Michael Warmuth (Exec. VP) 50, Paul Magill (Sr. VP) 51, Stephen Fussell (Sr. VP) 55, A. David Forrest (Sr. VP) 51,
No. of Employees: 91,000 No. of Shareholders: 60,476
| Last Annual | December 31st, 2012 |
| Last Interim | March 31st, 2013 |
| Shares in Issue | 1,558,864,658 |
| Free Float | 1.56bn (99.8%) |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | |
| Exchange |
London Stock Exchange |
| Eligible for | an ISA? a SIPP? |
| Address | C/O TAX DEPT D367 & AP6D,100 Abbott Park Road, ABBOTT PARK, 60064-3500, United States |
| Web | http://www.abbott.com |
| Phone | +1 847 9376100 |
| Contact | Brian Yoor (Vice President - Investor Relations) |
| Registrar | Computershare Trust Company |
| Auditors | Deloitte & Touche LLP |
